|Bid||1.6500 x 1100|
|Ask||1.6600 x 3100|
|Day's Range||1.6400 - 1.7200|
|52 Week Range||1.4600 - 3.9000|
|Beta (5Y Monthly)||0.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 10, 2021 - May 14, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.25|
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2020 and provided an update on key highlights for 2021.
CASI Pharmaceuticals (NASDAQ: CASI) was down by roughly 15% in late trading on Wednesday, against the more or less flat performance of the S&P 500 index. CASI announced Wednesday morning that it is issuing just under 15.9 million shares of its common stock at a price of $2.05 per share. CASI said it will utilize the monies "for working capital and general corporate purposes."
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public offering of 15,853,658 shares of its common stock at a price to the public of $2.05 per share. CASI has granted the underwriters an option to purchase up to an additional 2,378,048 shares of common stock, which terminates on the earlier of 30 days and the day before CASI files to the U.S. Securities and Exchange Commission ("SEC") its Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The offering is expected to close on or about March 26, 2021, subject to satisfaction of customary closing conditions. The gross proceeds to CASI from the offering, excluding any exercise by the underwriters of their option to purchase additional shares, are expected to be approximately $32.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by CASI.